Health Canada Approves First Human Trial for Experimental Cancer Drug
Posted on: Wednesday, 26 September 2007, 15:00 CDT
By THE CANADIAN PRESS
EDMONTON - Health Canada has approved a limited human trial for a cancer drug called DCA that has shown promise in studies in rats.
Dr. Evangelos Michelakis says in a letter posted on a University of Alberta website that the agency has approved a Phase 2 trial of the chemical to be conducted at the University of Alberta Hospital.
The researcher says the hospital will begin recruiting up to 50 people with certain types of advanced brain cancer over the next 18 months to take part in the trial.
DCA, which has been used to treat certain rare metabolic disorders in humans, is cheap and can't be patented.
Without a pharmaceutical company funding the drug's development, Michelakis and his team have been fundraising privately, and have raised $800,000 to go towards clinical trials.
The Canadian Cancer Society has warned people not to use the drug until it has been fully tested in humans, after reports some desperate cancer patients were trying to self-medicate with the chemical.
Source: Canadian Press
Related Articles
- CELSION Secures Special Protocol Assessment of Its Pivotal Phase III Liver Cancer Trial From FDA
- Pro-Pharmaceuticals Starts Dosing in Cancer Trial
- CTI Ends Key Lung Cancer Trial
- Pro-Pharmaceuticals Starts Colorectal Cancer Trial
- ZIOPHARM Announces Interim Results in ZIO-101 Phase I Solid Tumor Cancer Trial; Clinical Activity in Several Cancers
- Pro-Pharmaceuticals Retains Dr. James T. Gourzis to Provide Clinical Management & Strategic Development of Its Europe-Based Phase III Colorectal Cancer Trial
- Antigenics Updates Business Strategy and Outlines Timeline for the Analysis of Its Phase 3 Kidney Cancer Trial
- Cancer 'Wonder Drug' Brings New Hope for Women Treatment for Breast Disease Approved for Scots Patients
- The Father of Cox-2 Inhibitors Says Cancer Trials Should Continue
- Cancer Trial Starts
 |
 |
User Comments (0)
RSS Feeds